WAIKOLOA, Hawaii — To yield the benefits of interventional glaucoma treatment, ophthalmologists need a roadmap for how to implement it, according to a speaker here.
At the Hawaiian Eye 2026 meeting, Christine Funke, MD, said that acceptance of interventional glaucoma (IG) has been a slow process, likely due to lingering doubts about whether it is best for patients.
“I’m starting to wonder: How heavily do we believe in IG? Are we really ‘all in’ as a community, or are we skirting issue and not really using it in practice?” she said. “I think that if you're not seeing every single patient that